<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>3 mnotes | 　　　　</title>
  <meta name="description" content="3 mnotes | 　　　　" />
  <meta name="generator" content="bookdown 0.22 and GitBook 2.6.7" />

  <meta property="og:title" content="3 mnotes | 　　　　" />
  <meta property="og:type" content="book" />
  
  
  
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="3 mnotes | 　　　　" />
  
  
  




  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="catype.html"/>

<script src="libs/header-attrs-2.8/header-attrs.js"></script>
<script src="libs/jquery-3.5.1/jquery.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />









<link href="libs/anchor-sections-1.0.1/anchor-sections.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.0.1/anchor-sections.js"></script>
<script src="libs/htmlwidgets-1.5.3/htmlwidgets.js"></script>
<link href="libs/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet" />
<script src="libs/datatables-binding-0.18/datatables.js"></script>
<link href="libs/dt-core-1.10.20/css/jquery.dataTables.min.css" rel="stylesheet" />
<link href="libs/dt-core-1.10.20/css/jquery.dataTables.extra.css" rel="stylesheet" />
<script src="libs/dt-core-1.10.20/js/jquery.dataTables.min.js"></script>
<link href="libs/nouislider-7.0.10/jquery.nouislider.min.css" rel="stylesheet" />
<script src="libs/nouislider-7.0.10/jquery.nouislider.min.js"></script>
<link href="libs/selectize-0.12.0/selectize.bootstrap3.css" rel="stylesheet" />
<script src="libs/selectize-0.12.0/selectize.min.js"></script>
<link href="libs/dt-plugin-searchhighlight-1.10.20/source.css" rel="stylesheet" />
<script src="libs/dt-plugin-searchhighlight-1.10.20/jquery.highlight.js"></script>
<script src="libs/dt-plugin-searchhighlight-1.10.20/source.min.js"></script>
<link href="libs/crosstalk-1.1.1/css/crosstalk.css" rel="stylesheet" />
<script src="libs/crosstalk-1.1.1/js/crosstalk.min.js"></script>




<link rel="stylesheet" href="css/JhengHei.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="index.html#nanaoku"><strong>《nanaoku》</strong></a></li>
<li class="chapter" data-level="1" data-path="rawdoc.html"><a href="rawdoc.html"><i class="fa fa-check"></i><b>1</b> rawdoc</a></li>
<li class="chapter" data-level="2" data-path="catype.html"><a href="catype.html"><i class="fa fa-check"></i><b>2</b> catype</a></li>
<li class="chapter" data-level="3" data-path="mnotes.html"><a href="mnotes.html"><i class="fa fa-check"></i><b>3</b> mnotes</a>
<ul>
<li class="chapter" data-level="3.1" data-path="mnotes.html"><a href="mnotes.html#section"><i class="fa fa-check"></i><b>3.1</b> 700061689</a>
<ul>
<li class="chapter" data-level="3.1.1" data-path="mnotes.html"><a href="mnotes.html#section-1"><i class="fa fa-check"></i><b>3.1.1</b> 210517</a></li>
</ul></li>
<li class="chapter" data-level="3.2" data-path="mnotes.html"><a href="mnotes.html#section-2"><i class="fa fa-check"></i><b>3.2</b> 700072580</a>
<ul>
<li class="chapter" data-level="3.2.1" data-path="mnotes.html"><a href="mnotes.html#section-3"><i class="fa fa-check"></i><b>3.2.1</b> 210512</a></li>
</ul></li>
<li class="chapter" data-level="3.3" data-path="mnotes.html"><a href="mnotes.html#section-4"><i class="fa fa-check"></i><b>3.3</b> 700150240</a>
<ul>
<li class="chapter" data-level="3.3.1" data-path="mnotes.html"><a href="mnotes.html#section-5"><i class="fa fa-check"></i><b>3.3.1</b> 210510</a></li>
</ul></li>
<li class="chapter" data-level="3.4" data-path="mnotes.html"><a href="mnotes.html#section-6"><i class="fa fa-check"></i><b>3.4</b> 700180657</a>
<ul>
<li class="chapter" data-level="3.4.1" data-path="mnotes.html"><a href="mnotes.html#section-7"><i class="fa fa-check"></i><b>3.4.1</b> 999999</a></li>
</ul></li>
<li class="chapter" data-level="3.5" data-path="mnotes.html"><a href="mnotes.html#section-8"><i class="fa fa-check"></i><b>3.5</b> 700350999</a>
<ul>
<li class="chapter" data-level="3.5.1" data-path="mnotes.html"><a href="mnotes.html#section-9"><i class="fa fa-check"></i><b>3.5.1</b> 210510</a></li>
</ul></li>
<li class="chapter" data-level="3.6" data-path="mnotes.html"><a href="mnotes.html#section-10"><i class="fa fa-check"></i><b>3.6</b> 700385854</a>
<ul>
<li class="chapter" data-level="3.6.1" data-path="mnotes.html"><a href="mnotes.html#section-11"><i class="fa fa-check"></i><b>3.6.1</b> 210507</a></li>
</ul></li>
<li class="chapter" data-level="3.7" data-path="mnotes.html"><a href="mnotes.html#section-12"><i class="fa fa-check"></i><b>3.7</b> 700704174</a>
<ul>
<li class="chapter" data-level="3.7.1" data-path="mnotes.html"><a href="mnotes.html#section-13"><i class="fa fa-check"></i><b>3.7.1</b> 999999</a></li>
</ul></li>
<li class="chapter" data-level="3.8" data-path="mnotes.html"><a href="mnotes.html#section-14"><i class="fa fa-check"></i><b>3.8</b> 700990347</a>
<ul>
<li class="chapter" data-level="3.8.1" data-path="mnotes.html"><a href="mnotes.html#section-15"><i class="fa fa-check"></i><b>3.8.1</b> 210513</a></li>
</ul></li>
<li class="chapter" data-level="3.9" data-path="mnotes.html"><a href="mnotes.html#section-16"><i class="fa fa-check"></i><b>3.9</b> 701057711</a>
<ul>
<li class="chapter" data-level="3.9.1" data-path="mnotes.html"><a href="mnotes.html#section-17"><i class="fa fa-check"></i><b>3.9.1</b> 999999</a></li>
</ul></li>
<li class="chapter" data-level="3.10" data-path="mnotes.html"><a href="mnotes.html#section-18"><i class="fa fa-check"></i><b>3.10</b> 701252496</a>
<ul>
<li class="chapter" data-level="3.10.1" data-path="mnotes.html"><a href="mnotes.html#section-19"><i class="fa fa-check"></i><b>3.10.1</b> 210517</a></li>
</ul></li>
<li class="chapter" data-level="3.11" data-path="mnotes.html"><a href="mnotes.html#section-20"><i class="fa fa-check"></i><b>3.11</b> 701253142</a>
<ul>
<li class="chapter" data-level="3.11.1" data-path="mnotes.html"><a href="mnotes.html#section-21"><i class="fa fa-check"></i><b>3.11.1</b> 999999</a></li>
</ul></li>
<li class="chapter" data-level="3.12" data-path="mnotes.html"><a href="mnotes.html#section-22"><i class="fa fa-check"></i><b>3.12</b> 701257485</a>
<ul>
<li class="chapter" data-level="3.12.1" data-path="mnotes.html"><a href="mnotes.html#section-23"><i class="fa fa-check"></i><b>3.12.1</b> 999999</a></li>
</ul></li>
<li class="chapter" data-level="3.13" data-path="mnotes.html"><a href="mnotes.html#section-24"><i class="fa fa-check"></i><b>3.13</b> 701263241</a>
<ul>
<li class="chapter" data-level="3.13.1" data-path="mnotes.html"><a href="mnotes.html#section-25"><i class="fa fa-check"></i><b>3.13.1</b> 999999</a></li>
</ul></li>
<li class="chapter" data-level="3.14" data-path="mnotes.html"><a href="mnotes.html#section-26"><i class="fa fa-check"></i><b>3.14</b> 701265877</a>
<ul>
<li class="chapter" data-level="3.14.1" data-path="mnotes.html"><a href="mnotes.html#section-27"><i class="fa fa-check"></i><b>3.14.1</b> 999999</a></li>
</ul></li>
<li class="chapter" data-level="3.15" data-path="mnotes.html"><a href="mnotes.html#section-28"><i class="fa fa-check"></i><b>3.15</b> 701273749</a>
<ul>
<li class="chapter" data-level="3.15.1" data-path="mnotes.html"><a href="mnotes.html#section-29"><i class="fa fa-check"></i><b>3.15.1</b> 999999</a></li>
</ul></li>
<li class="chapter" data-level="3.16" data-path="mnotes.html"><a href="mnotes.html#section-30"><i class="fa fa-check"></i><b>3.16</b> 701284346</a>
<ul>
<li class="chapter" data-level="3.16.1" data-path="mnotes.html"><a href="mnotes.html#section-31"><i class="fa fa-check"></i><b>3.16.1</b> 210512</a></li>
</ul></li>
</ul></li>
</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">　　　　</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="mnotes" class="section level1" number="3">
<h1><span class="header-section-number">3</span> mnotes</h1>
<div id="section" class="section level2" number="3.1">
<h2><span class="header-section-number">3.1</span> 700061689</h2>
<div id="section-1" class="section level3" number="3.1.1">
<h3><span class="header-section-number">3.1.1</span> 210517</h3>
<p><strong>{tube feeding}</strong></p>
<p>the oral drug takepron (lansoprazole, 30mg/tab) in active medication should not be grinded, while it can be peeled in half.</p>
<p>there is also an iv version takepron (lansoprazole, 30mg/vial) can be the alternative.</p>
</div>
</div>
<div id="section-2" class="section level2" number="3.2">
<h2><span class="header-section-number">3.2</span> 700072580</h2>
<div id="section-3" class="section level3" number="3.2.1">
<h3><span class="header-section-number">3.2.1</span> 210512</h3>
<p><strong>{post IPP meeting following up}</strong></p>
<ul>
<li><p>the schedule with regimen for PBSCT for the patient is disclosed in the meeting.</p></li>
<li><p>the estimated total amount of busulfan used in the time table is 15 vials.</p>
<ul>
<li>based on busulfan 60mg/10mL/vial, dose 3.2mg/kg, body weight 85kg</li>
<li>5 vials per day for 3 days (2021-05-12, 2021-05-13, 2021-05-14)</li>
<li>pharmacy staff in charge of drug purchasing will get the inventory ready before the coming prescribing.</li>
</ul></li>
<li><p>people for dispensing regimen during weekend are also arranged.</p></li>
<li><p>preparation and administration precautions:</p>
<ul>
<li>busulfan:
<ul>
<li>do not use polycarbonate syringes or polycarbonate filter needles with the drug.</li>
</ul></li>
<li>etoposide:
<ul>
<li>precipitation may be exacerbated at concentrations of 0.4 mg/mL or above.</li>
<li>etoposide 400mg/m2 x body surface area 2m2 -&gt; amount 800mg.</li>
<li>total solution containing 800mg etoposide will be no less than 2000mL.</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-4" class="section level2" number="3.3">
<h2><span class="header-section-number">3.3</span> 700150240</h2>
<div id="section-5" class="section level3" number="3.3.1">
<h3><span class="header-section-number">3.3.1</span> 210510</h3>
<p><strong>{problem list}</strong></p>
<p>the active problems listed in the TPR sheet are shown as following:
- pneumonia
- UTI
- hypertension
- ileus
- hyponatremia</p>
<p>[objective]</p>
<ul>
<li>urine OB 1+ (2021-05-08)</li>
<li>urine bacteria 1+ (2021-05-08)</li>
<li>CRP 5.39 (2021-05-08)</li>
<li>D-dimer 1763ng/mL (2021-05-08)</li>
<li>hs-Troponin I 49pg/mL (2021-05-08)</li>
<li>Na 121mmol/L (2021-05-08)</li>
<li>BUN 57mg/dL (2021-05-08)</li>
<li>Creatinine 1.71mg/dL (2021-05-08)</li>
<li>WBC 15.55 (2021-05-08)</li>
<li>RBC 2.68 (2021-05-08)</li>
<li>MCV 97.4 (2021-05-08)</li>
<li>serum glucose 177mg/dL (2021-05-08)</li>
<li>no defecation recorded in these 2 days</li>
</ul>
<p>[assessment]</p>
<ul>
<li>vital signs, including blood pressure, looks relatively stable.</li>
<li>if no other special consideration exists, the first priority should be controlling the infections.</li>
<li>brosym 2000mg IVD Q12H has been prescribed to control the infection since 2021-05-09.</li>
<li>the lower serum sodium might be improved by intaking salted food.</li>
<li>lab data showed a higher serum glucose level, an one-point datum might not lead to its trend, more data to form a time series of blood sugar monitoring is recommended.</li>
<li>MCV almost touched the upper limit of the normal range, some folic acid and/or vit B12 supplements might be helpful for the mild anemia.</li>
<li>some laxative agent might be helpful for the ileus.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>keep abx using and monitoring changes of infection signs.</li>
<li>invite dietitian to help the patient to eat more salted diets and to see if any other diet issue found, then get sodium tested few days later.</li>
<li>order regular scheduled blood sugar tests to build its trend.</li>
<li>folacin (folic acid 5mg) and/or kentamin (thiamine 50mg, pyridoxine 50mg, cyannocobalamin 500mcg) are available in pharmacy inventory now, each of them could be administrated QD or BID, which is recommended.</li>
<li>if still no defecation before 2021-05-11, then dulcolax (bisacodyl 5mg) QD or BID could be considered to prescribe, and administrated until defecation or 3 days then reevaluate the condition.</li>
</ul>
</div>
</div>
<div id="section-6" class="section level2" number="3.4">
<h2><span class="header-section-number">3.4</span> 700180657</h2>
<div id="section-7" class="section level3" number="3.4.1">
<h3><span class="header-section-number">3.4.1</span> 999999</h3>
<p><strong>{colon cancer}</strong></p>
<p>[objective]</p>
<ul>
<li>2018-02 diagnosed with adenocarcinoma of S-colon, cT3N0M0.</li>
<li>2018-02-14 pathology
<ul>
<li>large intestine, sigmoid colon, laparoscopic LAR —- Adenocarcinoma, moderately differentiated.</li>
<li>IHC stains: EGFR (+), PMS2 (+), MSH 6 (+), MSH2 (+), MLH1 (+).</li>
<li>foci of mesenteric endometrosis, CK7 (+) and CK20 (-), with fibrosis.</li>
<li>AJCC 8th ed. staging: pT3N0 (cMx); pStage: IIA at least (if cM0).
<ul>
<li>primary tumor pT3 - tumor invades through the muscularis propria into pericolonic tissues</li>
<li>regional lymph nodes pN0 - no regional lymph node metastasis</li>
<li>distant Metastasis pMx<br />
</li>
</ul></li>
</ul></li>
<li>2018-12-25 CT: soft tissue mass with necrotic margin at surface of uterus up to 2.9cm in largest dimension which is new in comparison to CT dated on 2018-06-02.</li>
<li>2019-01-03 PET
<ul>
<li>a glucose hypermetabolic lesion on the superior aspect of the uterus. should be malignancy with pelvic seeding on the uterus.</li>
<li>increased FDG accumulation in the right lateral aspect of the abdomen and pelvic region and in the anterior aspect of the pelvic region.</li>
</ul></li>
<li>2019-01-04 sigmoidfiberscopy: an ulcerative tumor, about 1/3 circumferential bowel lumen at 18cm above AV (RS-colon) with easy contact bleeding previous anastomosis (10cm AAV) looked well.</li>
<li>2019-01-10 low anterior resection (LAR) and hysterectomy plus bilateral salpingo-oophorectomy (BSO) recurrent 3cm tumor (favor seeding) involving uterus and upper rectum and a segment of small bowel was identified.
<ul>
<li>IHC stains: CK20(+), CK7(focal+), vimentine(-)</li>
<li>patho: rT4bN0M1a, stage IVA.
2019-09-20 received 12th Avastin &amp; 14th FOLFOX6, mild fingers and feet numbness, pigmentation on breast skin.
2019-10-15 refilled Xeloda (capecitabine), mild fatigue, nausea, abdomen discomfort.
2019-11-26 refilled Xeloda (capecitabine), nail and finger pigmentation, mild fatigue and numbness.
2020-03-25 CT: a known newly-developed soft tissue nodule measuring 0.6 cm in right pelvic wall is noted again, increasing in size.
2020-04-07 PET</li>
<li>a glucose hypermetabolic lesion in the right anterior pelvic wall, compatible with a metastatic lesion.</li>
<li>multiple glucose hypermetabolic lesions in the left lower abdomen and in the pelvic cavity and a glucose hypermetabolic lesion in the left upper abdomen.
2020-11-07 CT: multiple soft tissue nodules in the peritoneum (upper abdomen and pelvic cavity), up to 1.7cm in left pelvic cavity, suspected peritoneal carcinomatosis.
2021-02-20 CT: progression of peritoneal tumors with left lower ureter invasion causing left hydronephrosis and hydroureter.</li>
</ul></li>
<li>CEA
<ul>
<li>2021-04-28 _8.64</li>
<li>2021-03-29 15.23</li>
<li>2021-03-02 16.89</li>
<li>2021-01-23 13.56</li>
<li>2020-10-28 _5.044</li>
<li>2020-06-22 12.062</li>
<li>2020-03-18 _8.714</li>
<li>2019-12-09 _2.008</li>
<li>2019-08-16 _0.866</li>
<li>2019-04-30 _1.534</li>
<li>2018-12-10 15.635</li>
<li>2018-09-10 _2.047</li>
</ul></li>
<li>regimen
<ul>
<li>2018-03-03 ~ __________: Ufur (tegafur + uracil)</li>
<li>__________ ~ 2020-07-03: FOLFOX + Avastin (bevacizumab)</li>
<li>2020-07-17 ~ 2021-02-19: FOLFIRI + Cyramza (ramucirumab)</li>
<li>2021-03-31 ~ up to now : RegoNivo (Opdivo (nivolumab) + Stivarga (regorafenib))</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>PMS2 (+), MSH 6 (+), MSH2 (+), MLH1 (+) -&gt; not dMMR, EGFR (+), pembrolizumab might not be indicated.</li>
<li>no KRAS/NRAS/BRAF lab data found.</li>
<li>after using 5-FU, FOLFOX plus anti-VEGF bevacizumab as adjuvant first-line therapy for more than one year (2018 Mar ~ 2020 Jul), the disease progressed, then the regimen was shifted to FOLFIRI plus anti-VEGFR2 ramucirumab as second-line therapy. the two regimen are listed in NCCN clinical practice guidelines.</li>
<li>the cancer has been progressed in 2020Q4 ~ 2021Q1, regimen shifted to RegoNivo since end of 2021 March.
<ul>
<li>nivolumab - anti-PD1, usually used in combination with anti-CTLA4 i.e. ipilimumab, to treat adults with metastatic colorectal cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and patient have tried treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.</li>
<li>regorafenib inhibits multiple kinases including VEGF1, VEGF2, VEGF3, PDGFR, FGFR involved in tumor angiogenesis and KIT, RET, RAF-1, BRAF involved in oncogenesis.</li>
<li>RegoNivo regimen is supported by articles, e.g. “<a href="https://pubmed.ncbi.nlm.nih.gov/32343640/">Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer</a>”</li>
</ul></li>
<li>possible toxicity for RegoNivo regimen
<ul>
<li>nivolumab can result in significant immune-mediated adverse reactions due to T-cell activation and proliferation. These immune-mediated reactions may involve any organ system, with the most common reactions being pneumonitis, enterocolitis, hepatitis, dermatitis, hypophysitis, nephritis, and thyroid dysfunction.</li>
<li>regorafenib:
<ul>
<li>hypertension occurs in nearly 30% of patients. usually occurs within 6 weeks of starting therapy and is well controlled with oral antihypertensive medications.</li>
<li>skin toxicity in the form of hand-foot syndrome and skin rash occur in up to 45% and 26%, respectively. generally appears within the first cycle of drug treatment.</li>
</ul></li>
</ul></li>
</ul>
<p>[suggest/plan]</p>
<ul>
<li>monitor any sign of toxicity caused by nivolumab and regorafenib.</li>
<li>keep tracking tumor markers including CEA</li>
<li>update chest, abdomen, and pelvic CT (and/or PET) every 3-6 months.</li>
</ul>
</div>
</div>
<div id="section-8" class="section level2" number="3.5">
<h2><span class="header-section-number">3.5</span> 700350999</h2>
<div id="section-9" class="section level3" number="3.5.1">
<h3><span class="header-section-number">3.5.1</span> 210510</h3>
<p><strong>{problem list}</strong></p>
<p>active problems listed in 2021-05-08 14:14 DutyNote containing 2 items:
- urinary tract infection
- right lower lung pneumonia</p>
<p>[subj/obj]</p>
<ul>
<li>admitted on 2021-05-08 for lethargy, weakness for 5 days and fever for 1 day.</li>
<li>with underlying HFrEF, bladder cancer s/p TURBT, HCVD, CKD and DM, been regularly followed up at our cardiology, urology, metabolism departments.</li>
<li>bladder cancer causing voiding difficulties and UTI</li>
<li>K 3.1mmol/L (2021-05-10), 3.1mmol/L (2021-05-08)</li>
<li>BUN 123mg/dL (2021-05-10), 101mg/dL (2021-05-08)</li>
<li>Creatinine 4mg/dL (2021-05-10), 3mg/dL (2021-05-08)</li>
<li>eGFR 15 (2021-05-10), 20 (2021-05-08)</li>
<li>CRP 8.63 (2021-05-10), 5.31 (2021-05-08)</li>
<li>RBC 4x10^6/uL (2021-05-10), 3.7x10^6/mL (2021-05-08)</li>
<li>HGB 11.6g/dL (2021-05-10), 10.8 (2021-05-08)</li>
<li>MCV 84.8 fL (2021-05-10), 86.2 fL (2021-05-08)</li>
<li>urine OB 2+, sediment-RBC 6-9, sediment-WBC &gt;= 100, Bacteria 3+ (2021-05-08)</li>
<li>hs-Troponin I 385pg/mL (2021-05-08)</li>
<li>serum glucose 177mg/dL (2021-05-08), records fluctuate between 126-226 from 2021-05-08 19:00 to 2021-05-10 11:30.</li>
<li>HbA1c 8.1 (2021-04-27), 8.6 (2021-03-01), 10.1 (2020-12-11), 9.6 (2020-09-17), 9.8 (2020-06-24)</li>
<li>Uric Acid 4.6mg/dL (2021-03-01), 6.1 (2021-01-19), 8.1 (2020-12-11), 9.3 (2020-09-17), 8.6 (2020-06-24)</li>
</ul>
<p>[assessment]</p>
<ul>
<li>vital signs looks relatively stable:
<ul>
<li>body temp no more than 37.5 degrees Celsius since 2021-05-08, the fever has subsided.</li>
<li>most of time SBP ranges in around 120-130, DBP 60-80, 3-day data showed BP is under well management.</li>
</ul></li>
<li>if there is no other special consideration, the first priority should be controlling the infections.
<ul>
<li>avelox (moxifloxacin) 400mg IVD QD has been administrated since 2021-05-09 and scheduled till 2021-05-15.</li>
<li>the patient has poor renal function, but no dosage adjustment necessary for avelox administration.</li>
</ul></li>
<li>although fever has gone, the rising CRP might hint the infection is still ongoing.</li>
<li>the lower serum potassium might caused by uretropic (furosemide).</li>
<li>lab data showed that blood suger flucturates in short-term (serum glucose), however the management is getting better in mid-term (HbA1c).
<ul>
<li>using humalog mix50 pen (insulin lispro 50%, insulin lispro protamine 50%) QDAC and QNAC now.</li>
</ul></li>
<li>MCV almost touched the lower limit of the normal range, some iron supplements might be helpful for boosting up the hemoglobin level.</li>
<li>uric acid seems fell into normal range for months, xanthine oxidase inhibitor could be no more necessary.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>keep abx using and monitoring any change of infection signs.</li>
<li>invite dietitian to help the patient to get more potassium-containing food, and/or consider to shift uretropic (furosemide) to potassium sparing spironolactone.</li>
<li>foliromin (ferrous sodium citrate, 50mg) BID for 2-4 weeks to levelup hemoglobin is recommended, administrated in combination with vit C to help absorption can be considered.</li>
<li>if there is no special consideration, discontinuation feburic (febuxostat) is recommended.</li>
</ul>
</div>
</div>
<div id="section-10" class="section level2" number="3.6">
<h2><span class="header-section-number">3.6</span> 700385854</h2>
<div id="section-11" class="section level3" number="3.6.1">
<h3><span class="header-section-number">3.6.1</span> 210507</h3>
<p><strong>{colon cancer}</strong></p>
<p>[subj/obj]</p>
<ul>
<li>diagnosed with sigmoid adenocarcinoma in 2020 Apr with liver, paraaortic LNs, and peritoneal carcinomatosis, cT3N2bM1c, stage IVc.</li>
<li>received FOLFIRI 80% dose and 11 times panitumumab from May to Oct in 2020 at Taoyuan General Hospital of Ministry of Health and Welfare.</li>
<li>patho colon biopsy on 2020-11-26 showed one huge tumor was noted at sigmoid colon (30cm from anal verge) and the lumen was near completely obstructed.</li>
<li>colonic tissue with invasive irregular neoplastic glands. immunohistochemical stains reveal CDX2(+) EGFR(+), PMS2(+), MLH1(focal +), MSH2(+), and MSH6(+).</li>
<li>received FOLFIRI 6 times from 2020 Nov to 2021 Mar (C1D1, C1D15, C2D1, C2D15, C3D1, C3D15) in our hospital prior to this hospitalization.</li>
<li>NRAS/KRAS reported on 2020-12-15 showing not detected.</li>
<li>CEA 16.62ng/mL(2021-01-26), 8.52ng/mL(2020-11-17).</li>
<li>BRAF lab data not found.</li>
</ul>
<p>[assessment]</p>
<ul>
<li>patients with tumors originating on the right side of the colon (hepatic flexure through cecum) are unlikely to respond to cetuximab and panitumumab in first-line therapy for metastatic disease.</li>
<li>EGFR(+), KRAS/NRAS WT gene and left-sided tumor - panitumumab is purchased and will be ready for the patient in days.</li>
<li>immune checkpoint inhibitors might not an ideal option for non-dMMR/MSI-H tumor - MLH1(focal +), MSH2(+), MSH6(+).</li>
<li>according to CEA lab data, the condition might not be improved after one year FOLFIRI.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>might order CT scan to gather new evidence on treatment effect.</li>
<li>If evidence shows that the cancer is getting more advanced, then shift FOLFIRI to FOLFOX or CAPEOX (each regimen can be used in combination with bevacizumab) could be considered.</li>
</ul>
<hr />
<p><strong>{substance dependence}</strong></p>
<p>[subj/obj]</p>
<ul>
<li>lab test showed evidence of using addictive drug.</li>
</ul>
<p>[assessment]</p>
<ul>
<li>should help the patient get rid of those illegal drugs.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>might arrange or refer the patient to an addiction treatment center or clinic to get some alternative e.g. methadone.</li>
</ul>
<hr />
<p><strong>{returning to society}</strong></p>
<p>[subj/obj]</p>
<ul>
<li>his family members avoid to contact him.</li>
<li>no job, no income</li>
<li>not standing on his own feet yet (financially)</li>
</ul>
<p>[assessment]</p>
<ul>
<li>being not reintegrated to the society will push him closer to the additive drugs.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>might arrange social work department staff to see if any help could be offered to him.</li>
</ul>
</div>
</div>
<div id="section-12" class="section level2" number="3.7">
<h2><span class="header-section-number">3.7</span> 700704174</h2>
<div id="section-13" class="section level3" number="3.7.1">
<h3><span class="header-section-number">3.7.1</span> 999999</h3>
<p><strong>{colon cancer}</strong></p>
<p>[objective]</p>
<ul>
<li>2019-09-20 screening for malignant neoplasm, colon: stool occult blood test positive</li>
<li>2019-10-03 colonofiberoscopy: an ulcerative lesion with lumen narrowing at 30 cm to 40 cm from anal verge and biopsy was done. impression: suspicion of sigmoid colon tumor.</li>
<li>2019-10-03 CT, abdomen:
<ul>
<li>wall thickening of sigmoid colon, 4.4 cm in length, with perifocal fat stranding.</li>
<li>sigmoid colon cancer T3N1MX.</li>
</ul></li>
<li>2019-10-14 laparoscopic anterior resection and anastomosis-malignant, finding:
<ul>
<li>sigmoid cancer 5<em>3</em>3cm near D-S junction with nearly total obstruction</li>
<li>splenic flexure was fully mobilized</li>
</ul></li>
<li>2019-10-16 patho:
<ul>
<li>sigmoid colon, laparoscopic sigmoid colectomy - adenocarcinoma</li>
<li>lymph node, mesocolic, dissection - positive for tumor metastasis (8/18) with extracapsular extension (6/8)</li>
<li>AJCC pathologic stage - pT3N2bMx, stage IIIC at least B.</li>
</ul></li>
<li>2020-01-16 CT, abdomen:
<ul>
<li>colon cancer s/p operation. focal fat stranding at LUQ.</li>
<li>left adrenal nodule (1.3cm).</li>
</ul></li>
<li>2020-05-07 sigmoidoscopy: no evidence of recurrence</li>
<li>2020-05-07 CT, abdomen, pelvis:
<ul>
<li>colon cancer s/p operation. focal fat stranding at LUQ without interval change.</li>
<li>left adrenal nodule (1.3cm) without interval change.</li>
</ul></li>
<li>2021-02-22 CT, abdomen:
<ul>
<li>tumor seeding in left paracolic gutter space is suspected. the differential diagnosis include epiploic appendagitis or omentum infarction.</li>
<li>metastatic nodes in para-aortic space and para-cava space are suspected.</li>
</ul></li>
<li>2021-02-27 whole body PET scan:
<ul>
<li>a glucose hypermetabolic lesion in the rectal region, probably tumor recurrence.<br />
</li>
<li>glucose hypermetabolic lesion at the C7 spine, probably tumor with distant metastasis.</li>
<li>increased FDG uptake in bilateral pulmonary hilar regions and the right shoulder, benign change is more likely.</li>
<li>s-colon cancer s/p treatment with tumor recurrence and C7 spine metastasis, rcTxN0M1a, r-staging IVA (AJCC 8th edi.)</li>
</ul></li>
<li>2021-03-09 sigmoidoscopy:
<ul>
<li>negative finding up to D-colon.</li>
<li>no evidence of local recurrence.</li>
</ul></li>
<li>2021-03-17 MRI, C-spine:
<ul>
<li>bony spinal canal stenosis in the middle and lower C-spine.</li>
<li>degenerative change in the middle and lower C-spine disc spaces</li>
<li>a heterogeneous enhancing tumor at C7 vertebral body.<br />
</li>
<li>degerative change at lower C-spine facet joints.</li>
</ul></li>
<li>CEA
<ul>
<li>2021-04-20 3.43ng/mL</li>
<li>2021-03-09 8.40ng/mL</li>
<li>2021-02-05 6.04ng/mL</li>
<li>2020-11-06 1.31ng/mL</li>
<li>2020-08-07 0.76ng/mL</li>
<li>2020-04-15 1.28ng/mL</li>
<li>2019-12-31 1.97ng/mL</li>
<li>2019-10-04 2.38ng/mL</li>
</ul></li>
<li>CA199
<ul>
<li>2021-04-20 9.11U/mL</li>
<li>2021-03-09 5.89U/mL</li>
</ul></li>
<li>regimen
<ul>
<li>2019-11-04 ~ 2020-04-13: FOLFOX</li>
<li>2021-03-18 ~ up to now : FOLFIRI, plus avastin (bevacizumab) and xgeva (denosumab) since 2021-04-02</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>no IHC stains (MSI, MMR) from patho report, no KRAS/NRAS/BRAF/HER2/NTRK found.</li>
<li>adjuvant treatment with FOLFOX 6 months s/p laparoscopic anterior resection.</li>
<li>the elevated CEA and CA199, together with PET and MRI imaging in Feb~Mar 2021 showed spine metastasis. the startup FOLFOX might not work anymore.</li>
<li>shift to FOLFIRI + bevacizumab + denosumab since Apr 2021. the former two are 2nd-line treatment and the last one is for the bone mets.
<ul>
<li>prior to the use of denosumab, dentist has been consulted for evaluating osteonecrosis of the jaw, ONJ.</li>
</ul></li>
<li>the treatments are followed the NCCN guidelines, no issue found.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>patients with the UGT1A1 7/7 genotype may be at increased risk for developing GI toxicity and myelosuppression. dose reduction should be considered in this setting.</li>
</ul>
</div>
</div>
<div id="section-14" class="section level2" number="3.8">
<h2><span class="header-section-number">3.8</span> 700990347</h2>
<div id="section-15" class="section level3" number="3.8.1">
<h3><span class="header-section-number">3.8.1</span> 210513</h3>
<p><strong>{Tube Feeding}</strong></p>
<p>all the oral drugs in current medication can be administrated via NG tube.</p>
<p>actein effervescent (acetylcysteine) should not be grinded, please dissolve the drug in adequate amount of drinking water prior to tube feeding.</p>
</div>
</div>
<div id="section-16" class="section level2" number="3.9">
<h2><span class="header-section-number">3.9</span> 701057711</h2>
<div id="section-17" class="section level3" number="3.9.1">
<h3><span class="header-section-number">3.9.1</span> 999999</h3>
<ul>
<li>D-colon cancer obstruction s/p self expandable metalic stent placed on 2020-07-16, and single-incision laparoscopic surgery (SILS) with left hemicolectomy on 2020-07-22</li>
<li>patho colon segmental resection for tumor reported on 2020-07-28:
<ul>
<li>tumor, descending colon, laparoscopic low anterior resection (LAR) - adenocarcinoma</li>
<li>lymph node, mesocolic, dissection - Tumor metastasis (2/16) without extracapsular extension (0/2).</li>
<li>AJCC pathologic staging pT4aN1b (if cM0), stage IIIB.</li>
<li>histology grade G2: moderately differentiated with focal tumor necrosis, abscess and mucin production.</li>
<li>ImmunoHistoChemistry for tumor cells:
EGFR(+, 100%), PMS2(+), MLH1(+), MSH2(+) and MSH6(+).</li>
</ul></li>
<li>mFOLFOX6 adjuvant chemotherapy 12 cycles from 2020-08-14 to 2021-01-22.</li>
<li>metastatic adenocarcinoma over left lower lung status post video-assisted thoracic surgery left lower lung wedge resection on 2021-02-26.</li>
<li>shift chemo regimen to FOLFIRI since 2021-03-26.</li>
</ul>
<p>Decreased chemotherapy dose to 67 % for grade 3 diarrhea with blody weight loss.
Decreased chemotherapy dose to 75 % for grade 2 diarrhea with blody weight loss.</p>
</div>
</div>
<div id="section-18" class="section level2" number="3.10">
<h2><span class="header-section-number">3.10</span> 701252496</h2>
<div id="section-19" class="section level3" number="3.10.1">
<h3><span class="header-section-number">3.10.1</span> 210517</h3>
<p><strong>{tube feeding}</strong></p>
<p>the oral drugs in active medication including:
- keto (ketorolac 10mg)
- neurontin (gabapentin 100mg)
- tramacet (tramadol 37.5mg, acetaminophen 325mg)</p>
<p>all the above drugs can be grinded and administrated via NG tube</p>
</div>
</div>
<div id="section-20" class="section level2" number="3.11">
<h2><span class="header-section-number">3.11</span> 701253142</h2>
<div id="section-21" class="section level3" number="3.11.1">
<h3><span class="header-section-number">3.11.1</span> 999999</h3>
<p>701253142</p>
<ul>
<li>2019-12-15 CT: cecal or appendiceal malignancy with adjacnet infiltration, few prominent regional lymph nodes and liver metastasis.</li>
<li>2020-02-10 bypass operation</li>
<li>2020-11-07 CT, ABD:
<ul>
<li>regression of cecum tumor and liver metastasis.</li>
<li>right adrenal tumor, suspect adrenal mestasis, mild progression.</li>
<li>liver cyst.</li>
<li>calcified granuloma in RUL.</li>
</ul></li>
<li>2021-02-22 CT, ABD:
<ul>
<li>stable condition of cecal tumor and liver metastases.</li>
<li>wall thickening of urinary bladder, right aspect.</li>
<li>mild regression of right adrenal tumor.</li>
</ul></li>
<li>2021-04-13 KUB:
<ul>
<li>S/P posterior instrumentation fixation from T10 To L5.</li>
<li>S/P laminectomy of L2, L3, and L4.</li>
<li>S/P partial laminectomy of L5</li>
<li>vacuum phenomenon of L4-5.</li>
<li>fecal material store in the colon.</li>
</ul></li>
<li>2021-04-15 KUB:
<ul>
<li>S/P posterior longitudinal transpedicular screws and rods fixation.</li>
<li>stool retention in the bowel.</li>
</ul></li>
<li>CEA
<ul>
<li>2021-05-11 _5.05ng/mL</li>
<li>2021-04-13 _5.63</li>
<li>2021-03-17 _4.50</li>
<li>2021-02-03 _5.34</li>
<li>2021-01-06 10.98</li>
<li>2020-12-22 16.63</li>
<li>2020-12-03 32.41</li>
<li>2020-11-05 40.06</li>
<li>2020-09-25 21.92</li>
</ul></li>
<li>CA199
<ul>
<li>2021-05-11 _24.28U/mL</li>
<li>2021-04-13 _27.14</li>
<li>2021-03-17 _25.11</li>
<li>2021-02-03 _26.37</li>
<li>2021-01-06 _31.50</li>
<li>2020-12-22 _41.91</li>
<li>2020-12-03 _95.77</li>
<li>2020-11-05 119.26</li>
<li>2020-09-25 119.70</li>
</ul></li>
<li>regimen:
<ul>
<li>2020-02-10 ~ 2020-11-xx: biweekly high dose 5-fluorouracil and leucovorin (HDFL)</li>
<li>2020-12-07 ~ up to now : biweekly <FOLFOX minus OX> plus several days of UFT (tegafur + uracil) at the beginning.</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-22" class="section level2" number="3.12">
<h2><span class="header-section-number">3.12</span> 701257485</h2>
<div id="section-23" class="section level3" number="3.12.1">
<h3><span class="header-section-number">3.12.1</span> 999999</h3>
<ul>
<li>Hx: chronic viral hepatitis B without delta-agent</li>
<li>2020-10-22 abdominal fullness without stool passage for days, lower abd mass with ascites -&gt; CT: focal wall thickening at sigmoid colon and descending colon junction with severely dilated proximal colon and ileum is found. colon cancer with obstruction is considered.</li>
<li>2020-10-23 sigmoidoscopy: one mass was noted in the DS colon with near total obstruction Size 3.6 cm. ( 50 cm from anal verge) s/p 9-cm stent under fluoroscopy.</li>
<li>2020-11-10 patho: colon, descending-sigmoid, left hemicolectomy - adenocarcinoma, moderately differentiated.
<ul>
<li>IHC stain: EGFR (+); PMS2 (+), MSH6 (+), MSH2(+), MLH1(+).</li>
<li>tissue labeled as ‘gastric superficial lesion’, biopsy - metastatic carcinoma.</li>
<li>staging: pT3pN0pM1c, pStage IVC.</li>
</ul></li>
<li>regimen
<ul>
<li>2020-11-27 ~ 2020-12-15, _3 times: FOLFIRI</li>
<li>2020-12-29 ~ 2021-05-13, 11 times: FOLFIRI + Avastin (bevacizumab)</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-24" class="section level2" number="3.13">
<h2><span class="header-section-number">3.13</span> 701263241</h2>
<div id="section-25" class="section level3" number="3.13.1">
<h3><span class="header-section-number">3.13.1</span> 999999</h3>
<p>701263241__999999__MNote</p>
<p><strong>{colon cancer}</strong></p>
<p>[objective]</p>
<ul>
<li><p>2019-05-21 colonoscopy: one ulceative mass lesion with lumen stenosis over 15 cm from anal verge, patho - adenocarcinoma.</p></li>
<li><p>2019-06-12 laparoscopic anterior resection and partial cystectomy, findings:</p>
<ul>
<li>sigmoid cancer with direct invasion to urinary bladder, enlarged LNs, and extraserosal surface invasion, but no peritoneal seedings, no liver surface lesion.</li>
<li>poorly differentiated, signet ring cell (+), lymphovascular invasion (+), perineural invasion (+), LN (+, 10/16), urinary bladder margin (+), pericolorectal tissues (+), MSH-6 intact, PMS-2 intact</li>
<li>ATCC 8 pT4bN2bMx, stage IIIC (if M0).</li>
</ul></li>
<li><p>2019-09-10 CT: recurrence over left pelvis, and omentum of LLQ.</p></li>
<li><p>stayed in USA for months, lost following up in Taiwan health care provider.</p></li>
<li><p>2021-01-04 CT abdomen: colon cancer s/p operation with peritoneal carcinomatosis with massive ascites, T0N0M1c, Stage IVC.</p></li>
<li><p>2021-04-06 CT abdomen, pelvis:</p>
<ul>
<li>massive ascites with suspected omental cake is found.</li>
<li>the severity of the ascites is stationary.</li>
<li>right pleural effusion, probably reactive pleural effusion.</li>
</ul></li>
<li><p>2021-04-16 ascites tapping: 3075cc clear yellowish ascites was drained.</p></li>
<li><p>2021-04-20 cyto, ascites: smears show clusters of pleomorphic tumor cells. the morphology is consistent with metastatic adenocarcinoma.</p></li>
<li><p>CEA</p>
<ul>
<li>2021-05-04 46.48ng/mL</li>
<li>2021-04-13 36.13ng/mL</li>
<li>2021-03-22 26.25ng/mL</li>
<li>2021-02-02 27.45ng/mL</li>
<li>2020-12-15 22.34ng/mL</li>
</ul></li>
<li><p>CA199</p>
<ul>
<li>2021-05-04 8.51U/mL</li>
<li>2020-12-15 8.63U/mL</li>
</ul></li>
<li><p>CA125</p>
<ul>
<li>2021-04-13 115.4U/mL</li>
<li>2021-03-22 _56.6U/mL</li>
<li>2021-02-02 _48.0U/mL</li>
<li>2020-12-15 _30.8U/mL</li>
</ul></li>
<li><p>regimen</p>
<ul>
<li>2019-09-23 ~ 2020-01-22: FOLFIRI plus bevacizumab, 8 times</li>
<li>2021-01-13 ~ up to now : FOLFIRI plus bevacizumab</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>KRAS/NRAS/BRAF not found in sheets</li>
<li>2 (MSH-6, PMS-2) of 4 MMR proteins remain intact, pembrolizumab might not be indicated.</li>
</ul>
</div>
</div>
<div id="section-26" class="section level2" number="3.14">
<h2><span class="header-section-number">3.14</span> 701265877</h2>
<div id="section-27" class="section level3" number="3.14.1">
<h3><span class="header-section-number">3.14.1</span> 999999</h3>
<p>701265877</p>
<p><strong>{Colon cancer}</strong></p>
<p>[subj/obj]</p>
<ul>
<li><p>(transverse) colon cancer with liver metastases, cT4aN1aM1c, stage IV s/p LPS right extended and hemicolectomy on 2020-03-26 and seedings over omentum found.</p>
<ul>
<li>patho peritoneum metastases, pT4aN2aM1c, stage IVc s/p radiofrequency ablation (RFA) with switch controller (SWC) x3 on 2020-08-25.</li>
<li>patho result: poorly differentiated, EGFR (+), wildtype RAS, proficient MMR but B-Raf V600E mutation.</li>
</ul></li>
<li><p>chemo (palliative) from 2020-04-27 with FOLFOXIRI (ox: self-paid; iri: insurance covered) with bevacizumab.</p></li>
<li><p>chest echography on 2021-02-23 showed right thorax pleural effusion s/p drainage of 600 cc.</p></li>
<li><p>CXR on 2021-03-09 showed right thorax small pleural effusion.</p></li>
<li><p>CEA:</p>
<ul>
<li>1.85ng/mL(2021-05-04)</li>
<li>1.35ng/mL(2021-04-20)</li>
<li>1.18ng/mL(2021-04-06)</li>
<li>1.59ng/mL(2021-03-23)</li>
<li>1.90ng/mL(2021-03-09)</li>
</ul></li>
<li><p>CA199:</p>
<ul>
<li>11764U/mL(2021-05-04)</li>
<li>4875U/mL(2021-04-20)</li>
<li>2068U/mL(2021-04-06)</li>
<li>1388U/mL(2021-03-23)</li>
<li>1557U/mL(2021-03-09)</li>
</ul></li>
</ul>
<p>for 3 consecutive weeks then 1 week off as a cycle</p>
<p>Oral target therapy with Cobimetinib 20mg 1# po QD (self-carried) (for 3 consecutive weeks then 1 week off as a cycle) from 2021/02/24~2021/0314.
Oral target therapy with Dabrafenib 75mg 2# po Q12H (self-carried) (for 3 consecutive weeks then 1 week off as a cycle) from 2021/02/24.
Chemotherapy with biweekly Erbitux(500mg)/Campto(100mg) (C1D1) on 2021/02/24, (C1D15) on 2021/03/10, (C2D1) on 2021/03/24, (C2D15) on 2021/04/07.
Oral target therapy with Mekinisc 2mg 1# po QDAC(self-paid) from 2021/03/15 (for 3 consecutive weeks then 1 week off as a cycle).
Therefore, the treatment would be cetuximab plus irinotecan(C1D15) and dabrafenib and MEK inhiitor, under the recognition of T-colon cancer with metastases to liver, peritoneum and pleura, and with B-Raf mutation.
This time, she was admitted for Chemotherapy with biweekly Erbitux(500mg)/Campto(100mg) (C3D1) on 2021/4/22.</p>
<p>Oral target therapy with Dabrafenib(Tafinlar) 75mg 1# po BID(self-carried) from 2021/02/24
Oral target therapy with Mekinisc 2mg 1# po QDAC(self pay) from 2021/03/15.
Chemotherapy with biweekly Erbitux(500mg)/Campto(100mg) (C3D1) from on 2021/04/23</p>
</div>
</div>
<div id="section-28" class="section level2" number="3.15">
<h2><span class="header-section-number">3.15</span> 701273749</h2>
<div id="section-29" class="section level3" number="3.15.1">
<h3><span class="header-section-number">3.15.1</span> 999999</h3>
<p>701273749__999999__MNote</p>
<p><strong>{colon cancer}</strong></p>
<p>[objective]</p>
<ul>
<li>2021-03-06 CT, abdomen: A-colon tumor with pericolonic fat stranding and enlarge lymphnode.</li>
<li>2021-03-07 laparoscopic right hemicolectomy for A-colon adenocarcinoma with obstruction, patho:
<ul>
<li>AJCC 8 staging: pT4aN2b, G3, IIIC</li>
<li>adenocarcinoma, poorly differentiated, with neuroendocrine feature.</li>
<li>tumor invades visceral peritoneum. bilateral resection margins are free.</li>
<li>mesocolonic lymph node: positive for tumor metastasis (10/14) with extranodal extension.</li>
</ul></li>
<li>CEA
<ul>
<li>2021-05-04: 1.35ng/mL</li>
<li>2021-04-02: 1.47ng/mL</li>
</ul></li>
<li>CA199
<ul>
<li>2021-05-04: _33.17U/mL</li>
<li>2021-04-02: 121.19U/mL</li>
</ul></li>
<li>regimen
<ul>
<li>FOLFOX since 2021-04-06</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>dMMR/MSI-H, KRAS/NRAS/BRAF lab data not found in sheets.</li>
<li>based on the short trend of CEA and CA199, we might consider the condition is relatively stable.</li>
<li>for ‘T4, N1-2’ or ‘T any, N2’ (high-risk stage III) stage which includes the patient, the preferred regimen as first-line adjuvant treatment could be:
<ul>
<li>CAPEOX 3-6 months or</li>
<li>FOLFOX 6 months,</li>
<li>other treatment options for this stage include:
<ul>
<li>Capecitabine 6 months or</li>
<li>5-FU 6 months</li>
</ul></li>
</ul></li>
<li>current regimen is the standard startup treatment without issue.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>have KRAS, NRAS, and BRAF mutation testing, microsatellite instability or mismatch repair testing done, even HER2, NTRK testing if possible.</li>
</ul>
</div>
</div>
<div id="section-30" class="section level2" number="3.16">
<h2><span class="header-section-number">3.16</span> 701284346</h2>
<div id="section-31" class="section level3" number="3.16.1">
<h3><span class="header-section-number">3.16.1</span> 210512</h3>
<p><strong>{drug identification}</strong></p>
<p>requesting drug identification for 6 items.</p>
<p>the 4 identified items has been shown as following while the other 2 items still remain unknown:
- sinemet (carbidopa 25mg, levodopa 100mg)
- urief (silodosin 4mg)
- rivotril (clonazepam 2mg)
- through (sennoside 12mg)</p>
<p>these drugs will be sent back to ward by the in-hospital porter.</p>

</div>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="catype.html" class="navigation navigation-prev navigation-unique" aria-label="Previous page"><i class="fa fa-angle-left"></i></a>

    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/lunr.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"toc": {
"collapse": "subsection"
}
});
});
</script>

</body>

</html>
